ARTGEN THERAPEUTICS

Artgen is developing novel non-viral gene therapies for treatment of vascular diseases. Their lead product candidate, ART-101, is a DNA plasmid designed to stimulate angiogenesis with the first indication directed for Peripheral Artery Disease (PAD). ART-101 expresses Vascular Endothelial Growth Factor (VEGF), one of the key regulators of angiogenesis. Artgen's platform technology has the potential for treatment of other vascular diseases.